Dementia, now known as major neurocognitive disorder, is not one monolithic disease. Nor is behavior disturbance driven by one particular neurocognitive dysfunction. In fact if we are able to understand it, behavior is an excellent form of nonverbal communication. There are many different causes of dementia. A major challenge with both researching and implementing interventions is viewing dementia and related behaviors as single entities. This approach leaves room for critical errors in the treatment of dementia patients, beginning with misdiagnosis.
This book approaches dementia by reviewing cognitive and functional assessments to provide a more accurate diagnosis, which then allows physicians to design specific interventions that are tailored to the person and their challenges. Because person centered care is vital to quality of life and longevity to an aging patient, this understanding of individual needs is vital.
Written by experts in the field, this book incorporates the latest evidence-based behavioral interventions matched to specific deficits. Behavioral management focuses not on controlling behavior, but using it to teach staff and caregivers how to interpret common actions and maximize function for people with major neurocognitive disorders. Quality of life and individualized care planning will be the theme and the book will provide practical case examples.
The book begins by introducing dementia and other neurocognitive illnesses, contextualizing them both historically and contemporarily. Next, the text focuses on the comprehensive assessment of a person with neurocognitive challenges in order to identify strengths and understand what the person is trying to communicate with their behavior. This process allows individualized care planning and behavioral (non-pharmacologic) management to meet the cognitive challenges and maximize individual strengths and thereby improve outcomes, making this a cutting edge resource.
GET IT FREE HERE
Neuroscientific research on emotion has developed dramatically over the past decade. The cognitive neuroscience of human emotion, which has emerged as the new and thriving area of “affective neuroscience,” is rapidly rendering existing overviews of the field obsolete.
This handbook provides a comprehensive, up-to-date, and authoritative survey of knowledge and topics investigated in this cutting-edge field. It covers a range of topics, from face and voice perception to pain and music, as well as social behaviors and decision making. The book considers and interrogates multiple research methods, among them brain imaging and physiology measurements, as well as methods used to evaluate behavior and genetics. Editors Jorge Armony and Patrik Vuilleumier have enlisted well-known and active researchers from more than twenty institutions across three continents, bringing geographic as well as methodological breadth to the collection. This timely volume will become a key reference work for researchers and students in the growing field of neuroscience.
Schizophrenia is a devastating disorder that has a profound impact on the lives of those diagnosed, and on the lives of those who care about them. The symptoms of schizophrenia can be frightening, confusing, and debilitating. Schizophrenia affects about 0.7 cases per 1000 worldwide, and accounts 3% of healthcare expenditures. About 80% of the direct costs of care for schizophrenia are associated with hospital or other residential care. Individuals with this diagnosis often experience cycles of remission and relapse throughout their lives. There is a need for ongoing research to identify and implement treatments that are effective in fostering both symptom reduction and social recovery.
GET IT FREE HERE
In 1993, the genetic mutation responsible for Huntington’s disease (HD) was identified. Considered a milestone in human genomics, this discovery has led to nearly two decades of remarkable progress that has greatly increased our knowledge of HD, and documented an unexpectedly large and diverse range of biochemical and genetic perturbations that seem to result directly from the expression of the mutant huntingtin gene.
Neurobiology of Huntington’s Disease: Applications to Drug Discovery presents a thorough review of the issues surrounding drug discovery and development for the treatment of this paradigmatic neurodegenerative disease. Drawing on the expertise of key researchers in the field, the book discusses the basic neurobiology of Huntington’s disease and how its monogenic nature confers enormous practical advantages for translational research, including the creation of robust experimental tools, models, and assays to facilitate discovery and validation of molecular targets and drug candidates for HD. Written to support future basic research as well as drug development efforts, this volume:
• Covers the latest research approaches in genetics, genomics, and proteomics, including high-throughput and high-content screening
• Highlights advances in the discovery and development of new drug therapies for neurodegenerative disorders
• Examines the practical realities of preclinical testing, clinical testing strategies, and, ultimately, clinical usage
While the development of effective drug treatments for Huntington’s disease continues to be tremendously challenging, a highly interactive and cooperative community of researchers and clinical investigators now brings us to the threshold of potential breakthroughs in the quest for therapeutic agents. The impressive array of drug discovery resources outlined in the text holds much promise for treating this devastating disease, providing hope to long-suffering Huntington’s disease patients and their families.
GET IT IT FREE HERE
Are we all at the mercy of our brain chemistry? Do you think that the amygdala and the hippocampus are fantastical sea monsters? What can an MRI scan tell us? Could you explain to dinner-party guests why we don’t giggle when we tickle ourselves? 30-Second Brain is here to fill your mind with the science of exactly what’s happening inside your head. Using no more that two pages, 300 words, and a single picture, this is the quickest way to understand the wiring and function of the most complex and intricate mechanism in the human body. Discover how the networks of 90 billion nerve cells work together to produce perception, action, cognition, and emotion. Explore how your brain defines your personality, and what it gets up to while you are asleep. Illustrated with mind-bending graphics and supported by biographies of pioneers in the field of neuroscience, it’s the book to get your gray matter thinking about your gray matter.
GET IT FREE HERE
A surprising number of disorders defy treatment with prescribed pharmaceuticals: a man’s hands shake so hard that he cannot hold anything; a woman is mired in severe, inescapable depression; or a child falls into severe epileptic seizures. For these patients and others, an alternative treatment is emerging for when pharmaceuticals fail: deep brain stimulation. More than 30,000 people worldwide undergo this treatment each year, and with this volume, Jamie Talan and Richard Firstman explain this cutting-edge medical development that may hold the key to unlocking some of medicine’s most bewildering mysteries.
GET IT FREE HERE
New and emerging directions in pharmaceutical research to better treat schizophrenia
Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics.
Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases.
Targets and Emerging Therapies for Schizophrenia presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined.
With contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia. Targets and Emerging Therapies for Schizophrenia:
• Provides a comprehensive resource for neuro-drug discovery and the development of molecular targets for schizophrenia treatment
• Draws from chemistry, biology, and pharmacology for more effective drug targeting and discovery
• Explores a wide range of receptors and molecular targets, including dopamine, PDEs, and neuropeptides
With Targets and Emerging Therapies for Schizophrenia as their guide, drug discovery and development scientists have the information they need to advance their own research so that new, more effective treatments for schizophrenia will soon be a reality.
GET IT FREE HERE